title: Gefitinib has the potential of activating cell immunity against malignant cells.
authors.forename: Shigenori
authors.initials: S
authors.lastname: Kanazawa
authors.forename: Mikiko
authors.initials: M
authors.lastname: Muramatsu
authors.forename: Yoshimi
authors.initials: Y
authors.lastname: Kinoshita
authors.forename: Kazuyuki
authors.initials: K
authors.lastname: Yamaguchi
authors.forename: Shosaku
authors.initials: S
authors.lastname: Nomura
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D014408:Biomarkers, Tumor / Q000378:metabolism*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000276:immunology* / Q000378:metabolism; D066246:ErbB Receptors / Q000037:antagonists & inhibitors / Q000378:metabolism*; D000077156:Gefitinib; D006801:Humans; D007111:Immunity, Cellular; D008175:Lung Neoplasms / Q000188:drug therapy / Q000276:immunology / Q000378:metabolism; D011799:Quinazolines / Q000627:therapeutic use*
chemical_list: D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor; D011799:Quinazolines; D066246:ErbB Receptors; D000077156:Gefitinib